Medicines | Horizonscan geneesmiddelen

Guanfacine ^G

ARI-0001 Blinatumomab ^IND Brexucabtagene autoleucel ^IND Crisantaspase Obecabtagene autoleucel Ponatinib ^IND

Ibudilast Masitinib Pridopidine Reldesemtiv Tofersen

Decitabine / cedazuridine Imetelstat Ivosidenib Luspatercept ^IND Magrolimab Olutasidenib Quizartinib

Acalabrutinib ^IND Axicabtagene ciloleucel ^IND

Brentuximab vedotin

Extension of indication to include in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) treatment of adult patients with previously untreated CD30+ peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). ^IND Extension of indication for ADCETRIS to include treatment for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone. ^IND

Epcoritamab Glofitamab Ibrutinib ^IND Lisocabtagene maraleucel ^IND Loncastuximab tesirine Odronextamab Pirtobrutinib Polatuzumab vedotin ^IND Tafasitamab Zamtocabtagene autoleucel

Apixaban ^IND Dabigatran ^G Tenecteplase ^IND

Depemokimab Tezepelumab

Aztreonam / avibactam Bezlotoxumab ^IND Ceftazidime / avibactam ^IND Durlobactam / sulbactam Faecal microbiota transplant Gepotidacin Peginterferon alfa-2a ^IND Ridinilazole Vonoprazan

Abnobaviscum 900 ^G Durvalumab ^IND Enfortumab vedotin ^IND Erdafitinib Inbakicept

Nivolumab

Extension of indication to include in combination with cisplatin-based chemotherapy the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. ^IND OPDIVO in combination with cisplatin-based chemotherapy is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. ^IND

Sacituzumab Govitecan ^IND Sasanlimab

Etrasimod Glepaglutide

Guselkumab

Tremfya is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve ziekte van Crohn die onvoldoende hebben gereageerd op, niet meer reageren op of intolerant waren voor conventionele behandeling of een biologische behandeling. ^IND Tremfya is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstige colitis ulcerosa die onvoldoende hebben gereageerd op, niet meer reageren op of intolerant waren voor conventionele behandeling of een biologische behandeling. ^IND

Mirikizumab

Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment Crohn's disease ^IND

Obefazimod ^IND Risankizumab ^IND Upadacitinib ^IND

Dabrafenib / trametinib Paclitaxel trevatide Vorasidenib

Atezolizumab ^IND Camizestrant Capivasertib

Datopotamab deruxtecan

Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with locally recurrent inoperable or metastatic Triple-Negative Breast Cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. ^IND Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with inoperable or metastatic HR-Positive, HER2-negative Breast Cancer who have been treated with one or two prior lines of systemic chemotherapy. ^IND

Elacestrant Inavolisib ^IND Olaparib ^IND Paclitaxel Palbociclib ^IND Ribociclib ^IND Sacituzumab govitecan ^IND

Trastuzumab deruxtecan

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy ^IND Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. ^IND Extension of indication to include treatment of HER2-low/ultra-low hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting. ^IND

Vepdegestrant

Acalabrutinib ^IND Iopofosine I 131 Pirtobrutinib ^IND

Zanubrutinib

Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL). ^IND Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy ^IND

Bosutinib ^IND

Dupilumab ^IND Ensifentrine

Casirivimab / imdevimab

Extension of indication to include treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40kg and receiving supplemental oxygen, who have a negative SARS-CoV-2 antibody test result. ^IND Extension of indication to include treatment of paediatric patients from 2 to less than 12 years old, weighing at least 10kg, who do not require supplemental oxygen and who are at increased risk of progression to severe COVID-19 for Ronapreve ^IND

Sabizabulin Vilobelimab

Cadonilimab Dostarlimab ^IND Olaparib ^IND Tisotumab vedotin

Fruquintinib Nivolumab ^IND Pembrolizumab / favezelimab Trifluridine / tipiracil ^IND

Ivacaftor / Tezacaftor / Elexacaftor ^IND Lumacaftor / ivacaftor ^IND Vanzacaftor

Blarcamesine Donanemab Lecanemab NE3107

Agomelatine ^IND Zuranolone

Dasiglucagon Deudomperidone Empagliflozine ^IND Insulin Icodec Insulin oral Regulatoire T-cellen (TREGS) Teplizumab

Fordadistrogene movaparvovec Givinostat Losmapimod Vamorolone Viltolarsen

Diazepam nasaal Ganaxolone

Avacincaptad pegol Bevacizumab-vikg Bimatoprost Botaretigene sparoparvovec Brimonidine tartrate/carbachol Faricimab ^IND Laruparetigene zosaparvovec Pegcetacoplan ^IND Phentolamine Polihexanide Ranibizumab Tarcocimab tedromer Varenicline Veligrotug

Olorofim Rezafungin

Axatilimab Mc0518

Dolutegravir/ abacavir /lamivudine ^IND Semzuvolimab

Atezolizumab ^IND Leukocyte interleukin Tislelizumab ^IND Xevinapant

Atogepant

Emicizumab ^IND Etranacogene dezaparvovec Fidanacogene elaparvovec Turoctocog alfa pegol ^IND Valoctocogene roxaparvovec Vonicog alfa ^IND

Brentuximab vedotin

Epcoritamab ^IND Lacutamab Tafasitamab ^IND Zanubrutinib ^IND

Cefepime / Enmetazobactam Cefepime/taniborbactam

Abexinostat Belzutifan Cabozantinib ^IND

Alirocumab ^IND

Evinacumab

Extension of indication to include the treatment of paediatric patients with homozygous familial hypercholesterolaemia (HoFH) aged 5 years and older ^IND Extension of indication for EVKEEZA to include the treatment of paediatric patients with homozygous familial hypercholesterolaemia aged 6 months to less than 5 years ^IND

Lomitapide ^IND Pravastatine/fenofibraat ^IND

Atezolizumab ^IND

Durvalumab

Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. ^IND Imfinzi as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). ^IND

Namodenoson Tremelimumab

Arachidyl amido cholanoic acid Elafibranor

Maralixibat

Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older. Extension of indication to include treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients 3 months of age and older ^IND

Obeticholic acid Odevixibat ^IND Resmetirom Seladelpar

Adagrasib Alectinib ^IND

Amivantamab

Amivantamab in combination with carboplatin and pemetrexed for the first‑line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations. ^IND Amivantamab in combination with chemotherapy is indicated for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) after osimertinib failure. ^IND Amivantamab in combination with lazertinib is indicated for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). ^IND

Atezolizumab

Subcutaneous formulation of atezolizumab for treatment of PD-(L)-1 Cancer Immunotherapy in multiple tumor types. ^IND Extension of indication to include first-line treatment of adult patients with non-small cell lung cancer (NSCLC) who are ineligible for platinum-based chemotherapy and who do not have EGFR mutant or ALK-positive disease, who have: locally advanced unresectable NSCLC not amenable for definitive chemoradiotherapy, or metastatic NSCLC. ^IND

Aumolertinib (mesilate) Cobolimab

Datopotamab deruxtecan

Datopotamab deruxtecan, in combination with Pembrolizumab, is indicated for the treatment of adult patients with advanced or metastatic NSCLC without actionable genomic alterations whose tumor has high programmed death-ligand 1 (PD-L1) expression (tumor proportion score; TPS ≥50%) and who have not previously received systemic therapy for advanced or metastatic NSCLC. ^IND Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer, who have received at least one systemic therapy

Domvanalimab

Durvalumab

Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND 1L advanced NSCLC ^IND Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab. ^IND Extension of indication to include IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements. ^IND

Encorafenib ^IND Ipilimumab ^IND Lazertinib Lenvatinib ^IND Nintedanib ^G

Nivolumab

OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥1% ^IND Extension of indication to include OPDIVO for the treatment of patients with resectable stage II-IIIB non-small cell lung cancer ^IND

Ociperlimab

Osimertinib

Osimertinib in combination with pemetrexed and platinum based chemotherapy for locally advanced (clinical stage IIIB, IIIC) or metastatic Non-Small Cell Lung Cancer (NSCLC) (clinical stage IVA or IVB) or recurrent Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy. ^IND Stage III unresectable Epidermal Growth Factor Receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) ^IND Extension of indication to include treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy. ^IND

Pembroliuzmab ^IND

Pembrolizumab

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum‑based chemotherapy. ^IND Keytruda, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non‑small cell lung carcinoma at high risk of recurrence in adults ^IND

Retifanlimab ^IND Sacituzumab Govitecan ^IND Serplulimab Sugemalimab

Tiragolumab

In combination with atezolizumab for first line treatment of locally advanced, unresectable Stage III Non-small cell lung cancer in adults and elderly who have no progression during or following concurrent platinum-based chemoradiotherapy. Tiragolumab in combination with Atezolizumab for first line treatment of locally advanced unresectable or metastatic high PD-L1, EGFR-negative, ALK-negative Non-small cell lung cancer in adults and elderly.

Tislelizumab

Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous non-small cell lung cancer who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC Tizveni in combination with pemetrexed and platinum‑containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC Extension of indication to include treatment of adult patients with non-small cell lung cancer (NSCLC) in combination and as monotherapy ^IND

Toripalimab ^IND Trastuzumab deruxtecan ^IND Tremelimumab

Benralizumab ^IND Brensocatib Gefapixant Mometasone furoate sinus drug depot Nintedanib ^IND Pamrevlumab Sotatercept Zinpentraxin alfa

Afamelanotide ^IND Avalglucosidase alfa Cipaglucosidase alfa Dasiglucagon ^IND Eliglustat ^IND Elinzanetant Encaleret Fezolinetant

Govorestat

Patients with Classic Galactosaemia aged 2 to 65 years. Sorbitol dehydrogenase deficiency

Leriglitazone N-Acetyl-L-Leucine Nedosiran Olezarsen Palopegteriparatide Paltusotine Pegunigalsidase alfa RGX-121 Sepiapterin Somapacitan Sparsentan Tiomolibdate choline

Ciltacabtagene autoleucel ^IND Daratumumab ^IND Elranatamab Idecabtagene vicleucel ^IND

Isatuximab

In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. ^IND In combination with bortezomib, lenalidomide and dexamethasone (Isa VRd) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplant.

Pomalidomide ^G Selinexor ^IND Talquetamab Teclistamab Venetoclax ^IND

Ublituximab

Baclofen / naltrexone / sorbitol Dantroleen ^G Daxibotulinumtoxine A Deoxythymidine / deoxycytidine Di-deuterated ethyl linoleate Eculizumab ^IND Efgartigimod Omaveloxolone Rozanolixizumab Satralizumab ^IND Zilucoplan

Avapritinib ^IND Momelotinib Navitoclax Pelabresib Pemigatinib ^IND

Clazosentan Deutetrabenazine (Extended release) Eplontersen Human normal immunoglobulin ^IND Nepla-tem-cel Ravulizumab ^IND Satralizumab Tiratricol ^G Tominersen Trofinetide Troriluzole

AL102 Afamitresgene autoleucel Catequentinib Efbemalenograstim alfa Entrectinib ^IND Futibatinib Melphalan hydrochloride NY-ESO-1 autologous engineered TCR-T cells Nirogacestat Nivolumab ^IND

Pembrolizumab

Indication for treatment in combination with gemcitabine and cisplatin, is indicated for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults. ^IND Extension of indication to include in combination with pemetrexed and platinum chemotherapy the first -line treatment of adults and adolescents aged 12 years and older with unresectable advanced or metastatic malignant pleural mesothelioma. ^IND

Repotrectinib

Retifanlimab

Patiënten met inoperabele, lokaal gevorderd of gemetastaseerd plaveiselcarcinoom van het anale kanaal. Zynyz is indicated as monotherapy for the first‑line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy

Selinexor ^IND Sugemalimab ^IND Tebentafusp

Tislelizumab

Tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy. Extension of indication to include in combination with platinum-based chemotherapy the first-line treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC)

Toripalimab

Toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”) Toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (“ESCC”)

Apremilast ^IND Arachis hypogaea (pinda) allergenen ^IND Atrasentan Avapritinib ^IND Budesonide ^IND Coacillium topical

Dupilumab

Dupixent is geindiceerd voor de behandeling van eosinofiele oesofagitis in volwassenen, adolescenten en kinderen van 1 jaar en ouder, die ongecontroleerd zijn op, intolerant zijn voor, of die geen kandidaat zijn voor conventionele therapie. ^IND Extension of indication to include treatment of moderate to severe chronic spontaneous urticaria in adults and adolescents 12 years and older, who are symptomatic despite treatment with H1 antihistamines and who are intolerant to or inadequately controlled by anti-IgE therapy for Dupixent. ^IND

Iptacopan ^IND Leniolisib Lorecivivint Marnetegragene autotemcel Obinutuzumab ^IND Ritlecitinib Sarilumab ^IND Sebetralstat Teprotumumab

Lenzilumab Obinutuzumab ^IND

Acoramidis Aficamten Bempedoic acid / ezetimibe ^IND Etripamil Ferric carboxymaltose Macitentan ^IND Macitentan / tadalafil Mavacamten Neoatricon (dopamine) Omecamtiv mecarbil Sotagliflozine ^IND Zalunfiban

Alpelisib Autologous human chondrocytes in vitro expanded C-type natriuretic peptide prodrug Copper histidine Linzagolix ^IND Pegzilarginase

Semaglutide

For weight management in people with obesity or who are overweight and have other related conditions. Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with obesity and body weight above 60 kg. Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose. ^IND Extension of indication to include risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and BMI ≥27 kg/m2. ^IND Op dit moment heeft oraal semaglutide reeds een indicatie voor diabetes. De aan te vragen indicatie uitbreiding zal slaan op het behandelen van obesitas. ^IND

Setmelanotide ^IND Setrusumab Tirzepatide ^IND Vosoritide ^IND

Apadamtase alfa Aprocitentan

Concizumab

Hemofilie A en B zonder inhibitors en een leeftijd van 12 jaar en ouder. ^IND Hemofilie A met inhibitors en hemofilie B met inhibitors, met een leeftijd van 12 jaar en ouder.

Crovalimab Danicopan Efanesoctocog alfa ^IND Exagamglogene autotemcel Giroctocogene fitelparvovec Hydroxycarbamide ^IND Iptacopan Luspatercept ^IND Marstacimab Mim 8 Mozafancogene autotemcel Pegcetacoplan ^IND Pozelimab Vadadustat

Dostarlimab ^IND Mirvetuximab soravtansine Olaparib ^IND Rucaparib ^IND

Gemcitabine Irinotecan in gepegyleerde liposomen ^IND

Lotilaner

Aglatimagene besadenovec Atezolizumab ^IND Degarelix ^G Enzalutamide ^IND Lutetium (177lu) vipivotide tetraxetan Niraparib ^IND Niraparib / abirateron Olaparib ^IND Radium-223 ^IND Relugolix Rucaparib ^IND Talazoparib ^IND

Bimekizumab

Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs), and for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy. ^IND Bimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). ^IND

Dapansutrile Sarilumab ^IND

Apitegromab Risdiplam ^IND

Roluperidon Xanomeline/ trospium

Daromun

Ipilimumab

Extension of indication to include in combination with nivolumab the treatment of adolescents (12 years of age and older) for advanced (unresectable or metastatic) melanoma. ^IND Neoadjuvant Ipilimumab Plus Nivolumab in Macroscopic Stage III Melanoma. ^IND

Lifileucel Nivolumab/relatlimab/hyaluronidase Ph20 Relatlimab / nivolumab Tucidinostat

Abrocitinib ^IND Beremagene geperpavec Bimekizumab ^IND Clascoterone Concentrate of proteolytic enzymes enriched in bromelain ^IND Delgocitinib Deucravacitinib Glycopyrronium ^IND Lebrikizumab Methotrexaat ^IND Nemolizumab Piclidenoson Prademagene zamikeracel Remibrutinib Rocatinlimab Roflumilast topicaal Secukinumab ^IND Spesolimab ^IND

Abatacept ^IND ECT-001-CB Nomacopan Treosulfan ^IND

Catumaxomab Domvanalimab

Pembrolizumab

Extension of indication for treatment with pembrolizumab plus trastuzumab in combination with standard of care chemotherapy for adults with HER2 positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma ^IND Treatment in the neoadjuvant or adjuvant setting of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. ^IND

Tislelizumab ^IND Trastuzumab deruxtecan ^IND Zolbetuximab

Selpercatinib ^IND

MDM2-p53 antagonist Selpercatinib ^IND Trastuzumab Deruxtecan ^IND

ARINA-1 Apremilast ^G Belzutifan Bulevirtide Colistimethate Sodium ^IND Decitabine / cedazuridine ^IND Mirabegron ^IND Molgramostim ^IND Mycofenolaatmofetil ^IND Olezarsen Pegcetacoplan ^IND Pembrolizumab ^IND Pitavastatine Relugolix / estradiol / norethisterone acetaat ^IND Vibegron

Bulevirtide Clesrovimab ^IND

Letermovir

Extension of indication to include treatment of prophylaxis of CMV disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-]. ^G Extension of Letermovir From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant. ^IND

Nirsevimab ^IND

Published on 4 June 2024

ADHD

ALL

ALS

AML / MDS

Aggressive non-Hodgkin’s lymphoma

Brentuximab vedotin

Antithrombotic medications

Asthma

Bacterial infections

Bladder cancer

Nivolumab

Bowel diseases

Guselkumab

Mirikizumab

Brain cancer

Breast cancer

Datopotamab deruxtecan

Trastuzumab deruxtecan

CLL

Zanubrutinib

CML

COPD

COVID-19

Casirivimab / imdevimab

Cervical cancer

Colon cancer

Cystic fibrosis

Dementia

Depression

Diabetes

Duchenne

Epilepsy

Eye disorders

Fungal infections

Graft versus Host

HIV

Head and neck cancer

Headache

Hemostasis promoting medication

Hodgkin's lymphoma

Indolent non-Hodgkin’s lymphoma

Infectious diseases other

Kidney cancer

Lipid-lowering medications

Evinacumab

Liver cancer

Durvalumab

Liver diseases

Maralixibat

Lung cancer

Amivantamab

Atezolizumab

Datopotamab deruxtecan

Durvalumab

Nivolumab

Osimertinib

Pembrolizumab

Tiragolumab

Tislelizumab

Lung diseases other

Metabolic diseases

Govorestat

Multiple Myeloma

Isatuximab

Multiple sclerosis

Muscular diseases other

Myeloproliferative disorders

Neurological disorders other

Oncology other

Pembrolizumab

Retifanlimab

Tislelizumab

Toripalimab

Other chronic immune diseases

Dupilumab

Other hematology

Other medication for cardiovascular diseases

Other metabolism and Endocrinology

Semaglutide